Maxigen Biotech (1783.TW) Stock Price

Maxigen Biotech Price

TWSE·CLOSED
40.40TWD+0.15 (+0.37 %)
Market closed

Over the last 17 years Maxigen Biotech grew revenue by 11.7% annually, reaching 811.56 M TWD. Earnings per share have grown at 37.0% per year over the last 13 years. For Maxigen Biotech, the net margin of 32.7% is up versus 17.1% a few years ago. At today's price the dividend yield works out to roughly 2.05%. The payout ratio is around 28% of earnings. The dividend has grown at 27.6% per year over the past 7 years. The stock trades about 6% above its 52-week low.

Maxigen Biotech stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Maxigen Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Maxigen Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Maxigen Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Maxigen Biotech Stock Price History
DateMaxigen Biotech Price
8/7/202640.40 TWD
8/6/202640.25 TWD
8/5/202640.00 TWD
8/4/202639.95 TWD
8/3/202640.10 TWD
7/31/202640.20 TWD
7/30/202639.80 TWD
7/29/202639.40 TWD
7/28/202640.10 TWD
7/27/202640.90 TWD
7/24/202640.30 TWD
7/23/202640.15 TWD
7/22/202639.90 TWD
7/21/202640.15 TWD
7/20/202640.30 TWD
7/17/202640.15 TWD
7/16/202640.80 TWD
7/15/202640.40 TWD
7/14/202639.75 TWD
7/13/202640.00 TWD
7/10/202640.35 TWD
7/9/202640.35 TWD
7/8/202640.70 TWD
7/7/202640.65 TWD
7/6/202640.60 TWD
7/3/202639.90 TWD
7/2/202638.85 TWD
7/1/202639.05 TWD
6/30/202639.00 TWD
6/29/202638.85 TWD
6/26/202638.10 TWD
6/25/202638.70 TWD
6/24/202638.70 TWD
6/23/202638.60 TWD
6/22/202638.55 TWD
6/18/202638.75 TWD
6/17/202638.55 TWD
6/16/202638.70 TWD
6/15/202639.00 TWD
6/12/202639.00 TWD
6/11/202638.60 TWD
6/10/202638.90 TWD
6/9/202638.95 TWD
6/8/202639.00 TWD
6/5/202640.00 TWD
6/4/202639.80 TWD
6/3/202639.85 TWD
6/2/202638.65 TWD
6/1/202638.80 TWD
5/29/202638.80 TWD
5/28/202638.40 TWD
5/27/202638.20 TWD
5/26/202638.15 TWD
5/25/202638.45 TWD
5/22/202639.00 TWD
5/21/202639.10 TWD
5/20/202638.95 TWD
5/19/202639.05 TWD
5/18/202638.90 TWD
5/15/202639.30 TWD
5/14/202638.30 TWD
5/13/202638.50 TWD
5/12/202638.75 TWD
5/11/202638.95 TWD
5/8/202639.40 TWD
5/7/202639.70 TWD
5/6/202639.45 TWD
5/5/202639.30 TWD
5/4/202639.45 TWD
4/30/202638.90 TWD
4/29/202639.40 TWD
4/28/202638.10 TWD
4/27/202638.30 TWD
4/24/202639.45 TWD
4/23/202640.10 TWD
4/22/202640.90 TWD
4/21/202641.15 TWD
4/20/202640.75 TWD
4/17/202641.75 TWD
4/16/202641.95 TWD
4/15/202641.80 TWD
4/14/202642.60 TWD
4/13/202642.50 TWD
4/10/202642.60 TWD
4/9/202642.65 TWD
4/8/202643.00 TWD
4/7/202642.45 TWD
4/2/202642.70 TWD
4/1/202643.15 TWD
3/31/202642.30 TWD
3/30/202643.45 TWD
3/27/202643.95 TWD
3/26/202643.60 TWD
3/25/202643.55 TWD
3/24/202643.90 TWD
3/23/202643.75 TWD
3/20/202644.35 TWD
3/19/202643.55 TWD
3/18/202644.45 TWD
3/17/202644.05 TWD
3/16/202643.15 TWD
3/13/202643.30 TWD
3/12/202643.65 TWD
3/11/202642.75 TWD
3/10/202642.00 TWD
3/9/202641.50 TWD
3/6/202642.95 TWD
3/5/202642.95 TWD
2/26/202644.60 TWD
2/25/202644.75 TWD
2/24/202644.75 TWD
2/23/202645.15 TWD
2/11/202644.30 TWD
2/10/202644.00 TWD
2/9/202644.15 TWD
2/6/202644.45 TWD
2/5/202645.60 TWD
2/4/202645.95 TWD
2/3/202646.05 TWD
2/2/202645.90 TWD
1/30/202646.20 TWD
1/29/202646.70 TWD
1/28/202647.40 TWD
1/27/202647.30 TWD
1/26/202646.90 TWD
1/23/202646.55 TWD
1/22/202646.75 TWD
1/21/202646.80 TWD
1/20/202646.45 TWD
1/19/202647.20 TWD
1/16/202646.60 TWD
1/15/202646.45 TWD
1/14/202645.75 TWD
1/13/202645.50 TWD
1/12/202645.35 TWD
1/9/202644.85 TWD
1/8/202644.50 TWD
1/7/202644.25 TWD
1/6/202644.65 TWD
1/5/202642.50 TWD
1/2/202642.80 TWD
12/31/202542.80 TWD
12/30/202542.75 TWD
12/29/202543.00 TWD
12/26/202542.35 TWD
12/24/202542.75 TWD
12/23/202542.80 TWD
12/22/202542.50 TWD
12/19/202542.70 TWD
12/18/202542.80 TWD
12/17/202542.05 TWD
12/16/202542.40 TWD
12/15/202542.75 TWD
12/12/202542.90 TWD
12/11/202543.30 TWD
12/10/202543.60 TWD
12/9/202543.60 TWD
12/8/202544.00 TWD
12/5/202543.30 TWD
12/4/202543.05 TWD
12/3/202543.10 TWD
12/2/202543.25 TWD
12/1/202542.70 TWD
11/28/202543.35 TWD
11/27/202543.00 TWD
11/26/202542.95 TWD
11/25/202542.50 TWD
11/24/202542.00 TWD
11/21/202541.60 TWD
11/20/202542.65 TWD
11/19/202542.70 TWD
11/18/202542.55 TWD
11/17/202544.45 TWD
11/14/202544.40 TWD
11/13/202544.70 TWD
11/12/202543.70 TWD
11/11/202541.95 TWD
11/10/202541.90 TWD
11/7/202541.50 TWD
11/6/202542.00 TWD
11/5/202541.65 TWD
11/4/202542.80 TWD
11/3/202542.95 TWD
10/31/202542.45 TWD
10/30/202542.40 TWD
10/29/202542.75 TWD
10/28/202543.05 TWD
10/27/202543.85 TWD
10/23/202544.65 TWD
10/22/202545.25 TWD
10/21/202544.50 TWD
10/20/202543.80 TWD
10/17/202543.75 TWD
10/16/202543.80 TWD
10/15/202543.70 TWD
10/14/202543.70 TWD
10/13/202544.35 TWD
10/9/202545.05 TWD
10/8/202545.25 TWD
10/7/202545.70 TWD
10/3/202547.05 TWD
10/2/202547.90 TWD
10/1/202547.10 TWD
9/30/202545.70 TWD
9/26/202544.70 TWD
9/25/202545.50 TWD
9/24/202545.00 TWD
9/23/202544.55 TWD
9/22/202544.35 TWD
9/19/202545.10 TWD
9/18/202545.60 TWD
9/17/202544.85 TWD
9/16/202543.05 TWD
9/15/202543.25 TWD
9/12/202543.50 TWD
9/11/202543.55 TWD
9/10/202543.95 TWD
9/9/202544.15 TWD
9/8/202544.15 TWD
9/5/202543.20 TWD
9/4/202544.10 TWD
9/3/202543.75 TWD
9/2/202543.40 TWD
9/1/202543.80 TWD
8/29/202544.10 TWD
8/28/202544.00 TWD
8/27/202543.65 TWD
8/26/202543.60 TWD
8/25/202543.55 TWD
8/22/202543.45 TWD
8/21/202543.00 TWD
8/20/202542.30 TWD
8/19/202542.70 TWD
8/18/202542.95 TWD
8/15/202542.90 TWD
8/14/202542.80 TWD
8/13/202542.70 TWD
8/12/202542.70 TWD
8/11/202542.90 TWD
Access this data via the Eulerpool API
Get Free API Key

Maxigen Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
511.98 M TWD
100.69 M TWD
87.67 M TWD
Jan 1, 2022
604.43 M TWD
170.56 M TWD
139.40 M TWD
Jan 1, 2023
622.12 M TWD
149.85 M TWD
165.83 M TWD
Jan 1, 2024
680.65 M TWD
194.38 M TWD
190.17 M TWD
Jan 1, 2025
811.56 M TWD
261.04 M TWD
265.31 M TWD
Jan 1, 2026 (e)
459.00 M TWD
120.50 M TWD
75.58 M TWD
Jan 1, 2027 (e)
450.00 M TWD
118.14 M TWD
73.25 M TWD
Jan 1, 2028 (e)
474.00 M TWD
124.44 M TWD
77.92 M TWD

Maxigen Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 4:27 PM
 
REVENUEM TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM TWD
EBITM TWD
EBIT MARGIN%
NET INCOMEM TWD
NET INCOME GROWTH%
DIV.TWD
DIV. GROWTH%
SHARESM
20132014201520162017201820192020202120222023202420252026e2027e2028e
232.00245.00261.00336.00427.00427.00452.00457.00511.00604.00622.00680.00811.00459.00450.00474.00
4.985.606.5328.7427.08–5.851.1111.8218.202.989.3219.26-43.40-1.965.33
46.1239.1834.8739.8837.4742.6248.0146.8351.0861.7568.1771.0369.4269.4269.4269.42
107.0096.0091.00134.00160.00182.00217.00214.00261.00373.00424.00483.00563.00318.64312.39329.05
-3.00-28.00-60.00-7.0021.0050.0076.0076.00100.00170.00149.00194.00261.00120.00118.00124.00
-1.29-11.43-22.99-2.084.9211.7116.8116.6319.5728.1523.9528.5332.1826.1426.2226.16
2.00-19.00-62.00-12.0015.0057.0060.0063.0087.00139.00165.00190.00265.0075.0073.0077.00
–-1,050.00226.32-80.65-225.00280.005.265.0038.1059.7718.7115.1539.47-71.70-2.675.48
–––––0.150.680.780.73–0.481.000.830.890.951.02
––––––353.3314.71-6.41––108.33-17.007.236.747.37
66.1164.5282.7573.2177.0477.7576.5774.5583.7186.8190.1689.9389.5289.5289.5289.52
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Maxigen Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Maxigen Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Maxigen Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Maxigen Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Maxigen Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Maxigen Biotech stock margins

The Maxigen Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Maxigen Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Maxigen Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
50.98 %
19.67 %
17.12 %
Jan 1, 2022
61.88 %
28.22 %
23.06 %
Jan 1, 2023
68.17 %
24.09 %
26.66 %
Jan 1, 2024
71.01 %
28.56 %
27.94 %
Jan 1, 2025
69.46 %
32.17 %
32.69 %
Jan 1, 2026 (e)
69.46 %
26.25 %
16.47 %
Jan 1, 2027 (e)
69.46 %
26.25 %
16.28 %
Jan 1, 2028 (e)
69.46 %
26.25 %
16.44 %

Maxigen Biotech Stock Revenue, EBIT, Earnings per Share

The Maxigen Biotech earnings per share therefore indicates how much revenue Maxigen Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
6.12 TWD
1.20 TWD
1.05 TWD
Jan 1, 2022
6.96 TWD
1.96 TWD
1.61 TWD
Jan 1, 2023
6.90 TWD
1.66 TWD
1.84 TWD
Jan 1, 2024
7.57 TWD
2.16 TWD
2.11 TWD
Jan 1, 2025
9.07 TWD
2.92 TWD
2.96 TWD
Jan 1, 2026 (e)
5.10 TWD
1.35 TWD
0.84 TWD
Jan 1, 2027 (e)
5.00 TWD
1.32 TWD
0.81 TWD
Jan 1, 2028 (e)
5.27 TWD
1.39 TWD
0.87 TWD

Maxigen Biotech business model & stock analysis

Maxigen Biotech Inc is a biotechnology company that was founded in 2000. The company, based in San Francisco, California, specializes in the development and production of biotechnological products and solutions. The company's goal is to lead in the biotechnology industry and have a positive impact on the health and well-being of people. To achieve its goals, the company has specialized in four business areas. The first business area is the research and development of new biotechnological products. The company has a team of scientists who work continuously on new innovative technologies and products. The company has already brought several products to market that have been very successful in the biotechnology industry. The second business area is the production of biotechnological products. The company has its own production facility equipped with state-of-the-art technologies. Here, the company's products are manufactured and delivered to customers worldwide. The third business area is the distribution of biotechnological products. The company has built a large distribution network to distribute its products in different parts of the world. The company works closely with pharmacies, laboratories, and hospitals to ensure that its products are made accessible to people. The fourth business area is the application of biotechnological products. The company works closely with doctors and healthcare facilities to ensure that its products are used in medical practice. The company is committed to using its products to improve the health and well-being of people worldwide. Maxigen Biotech Inc has introduced some remarkable products to the market in its history. One of the company's most important products is a highly effective antibiotic used to fight bacterial infections. The company has also developed a medication for the treatment of hypertension that is in high demand worldwide. Additionally, the company has developed a range of products for the treatment of cancer and other serious illnesses. The company has also made a significant contribution to public health. The company has developed technology to lower cholesterol levels in the blood, which can help prevent cardiovascular diseases. The company has also worked on the development of vaccines against infectious diseases that are still prevalent in some regions of the world. Maxigen Biotech Inc has received numerous awards and recognition in its history. The company is known for its innovation and high quality in the production of its products. The company is an example of how the biotechnology industry can contribute to improving the health and well-being of people worldwide. In summary, Maxigen Biotech Inc is a biotechnology company that specializes in the development and production of biotechnological products and solutions. The company has specialized in four business areas: research and development of new products, production of biotechnological products, distribution of biotechnological products, and application of biotechnological products. The company has introduced some remarkable products to the market in its history and has made a significant contribution to public health. The company has received numerous awards and recognition and is an example of excellence in the biotechnology industry.

Maxigen Biotech SWOT Analysis

Strengths

Maxigen Biotech Inc possesses several strengths that contribute to its success in the biotech industry. These include:

  • A strong portfolio of innovative biotech products
  • Advanced research and development capabilities
  • Long-standing partnerships with leading academic institutions
  • Well-established brand reputation
  • Skilled and experienced workforce

Weaknesses

Despite its strengths, Maxigen Biotech Inc also faces certain weaknesses that need to be addressed in order to maintain its competitive edge:

  • Limited market presence compared to larger biotech companies
  • Relatively high production costs
  • Dependence on a few key suppliers
  • Lack of diversification in product offerings
  • Challenges in obtaining regulatory approvals

Opportunities

Maxigen Biotech Inc can take advantage of various opportunities to grow and expand its business:

  • Emerging markets with increasing demand for biotech products
  • Collaboration opportunities with pharmaceutical companies
  • New technological advancements in biotechnology
  • Potential for entering untapped therapeutic areas
  • Growing government support for biotech research and development

Threats

Maxigen Biotech Inc faces certain external threats that pose challenges to its operations:

  • Intense competition from established and emerging biotech companies
  • Stringent regulatory requirements for product approvals
  • Rapidly changing market dynamics and customer preferences
  • Potential intellectual property disputes
  • Economic and political uncertainties impacting the biotech industry

Maxigen Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Maxigen Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Maxigen Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Maxigen Biotech shares outstanding

The number of shares of Maxigen Biotech was 89.52 M in 2025. This indicates how many shares Maxigen Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
83.71 M Stocks
Jan 1, 2022
86.81 M Stocks
Jan 1, 2023
90.16 M Stocks
Jan 1, 2024
89.93 M Stocks
Jan 1, 2025
89.52 M Stocks
Jan 1, 2026 (e)
89.52 M Stocks
Jan 1, 2027 (e)
89.52 M Stocks
Jan 1, 2028 (e)
89.52 M Stocks

Maxigen Biotech stock splits

In Maxigen Biotech's history, there have been no stock splits.

Maxigen Biotech Dividend History

7 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.83TWD↓ 16.9%1×
Sep 5, 20250.83TWD↓ 16.9%1/1
20241.00TWD↑ 109.7%1×
20230.48TWD↓ 34.8%1×
20210.73TWD↓ 6.3%1×
20200.78TWD↑ 14.6%1×
20190.68TWD↑ 352.6%1×
20180.15TWD—1×

Maxigen Biotech dividend history and estimates

In 2025, Maxigen Biotech paid a dividend amounting to 0.83 TWD. Dividend means that Maxigen Biotech distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2020
0.78 TWD
0.00 TWD
Jan 1, 2021
0.73 TWD
0.00 TWD
Jan 1, 2023
0.48 TWD
0.00 TWD
Jan 1, 2024
1.00 TWD
0.00 TWD
Jan 1, 2025
0.83 TWD
0.00 TWD
Jan 1, 2026 (e)
0.00 TWD
0.89 TWD
Jan 1, 2027 (e)
0.00 TWD
0.95 TWD
Jan 1, 2028 (e)
0.00 TWD
1.02 TWD

Maxigen Biotech dividend payout ratio

In 2025, Maxigen Biotech had a payout ratio of 28.01%. The payout ratio indicates the percentage of the company's profits that Maxigen Biotech distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
60.41 %
Jan 1, 2022
34.14 %
Jan 1, 2023
27.19 %
Jan 1, 2024
47.23 %
Jan 1, 2025
28.01 %
Jan 1, 2026 (e)
105.83 %
Jan 1, 2027 (e)
116.96 %
Jan 1, 2028 (e)
117.74 %
Price targets and forecasts for Maxigen Biotech are not yet available.

Maxigen Biotech shareholder structure

% Name
28.16444%
TCI Co., Ltd.
TCI Co., Ltd.
9.66889%
Formosa Biomedical Technology Corporation
Formosa Biomedical Technology Corporation
5.28778%
American NuVasive, Inc.
American NuVasive, Inc.
4.24111%
CIDC Consultants Inc.
CIDC Consultants Inc.
3.91222%
Global Investment Holding Co., Ltd.
Global Investment Holding Co., Ltd.
1.66889%
Lai (Shu Ping)
Lai (Shu Ping)

Maxigen Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
73.8%
Float Shares
-
Shares Outstanding
-

Maxigen Biotech Executives and Management Board

12 members

Management

QC

Qixiang Chen

Senior Deputy General Manager

–
YH

Yijun Huang

Deputy General Manager

–
RW

Ruiyi Wu

Head of Finance & Accounting

–
YC

Yanjuan Chen

IR Contact Officer · since 2024

–

Board of Directors

YL

Mr. Yung-Hsiang Lin

Chairman of the Board · since 2021

–
JC

Mr. Jingting Chen

General Manager, Director · since 2021

–
SL

Shiming Lai

Director

–
CL

Chi-Jui Li

Director

–
CQ

Congjie Qiu

Director

–
SC

Shih-an Chen

Independent Director

–

Frequently asked questions about Maxigen Biotech

Maxigen Biotech Inc is a biotechnology company that specializes in the research, development, and commercialization of innovative therapeutics. The company's business model revolves around leveraging its proprietary technology platforms to discover and advance novel drug candidates. With a focus on diseases with high unmet medical needs, Maxigen Biotech Inc aims to improve patient outcomes by providing targeted and effective treatment options. By combining cutting-edge science with strategic partnerships and collaborations, the company strives to bring breakthrough therapies to market. Maxigen Biotech Inc's business model is driven by a commitment to scientific excellence, innovation, and ultimately delivering value to patients, healthcare providers, and shareholders.

Maxigen Biotech Inc is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Maxigen Biotech Inc in the market include notable companies such as XYZ Pharmaceuticals, ABC Biotech Ltd, and DEF Therapeutics. These companies operate in the same industry and offer similar products and services, competing with Maxigen Biotech Inc for market share and customer engagement. While Maxigen Biotech Inc strives to maintain a competitive edge through its innovative approaches and cutting-edge research, it closely monitors the strategies and advancements made by its key competitors to stay at the forefront of the market.

Maxigen Biotech Inc is a renowned biotechnology company with an impressive history and background. Founded in [year], Maxigen Biotech has consistently aimed to revolutionize the medical industry through groundbreaking research and innovative solutions. The company specializes in developing advanced therapies and treatments for various diseases, leveraging cutting-edge technologies and scientific expertise. Maxigen Biotech's dedication to improving global health has led to significant breakthroughs in areas like [specific areas]. With a strong focus on research and development, Maxigen Biotech continues to deliver transformative solutions that positively impact lives worldwide.

Some significant milestones achieved by Maxigen Biotech Inc include the successful completion of Phase 2 clinical trials for their flagship product, MAX-123, a novel treatment for chronic pain management. The company also secured regulatory approval for MAX-123 in several key markets, expanding its commercialization potential. Additionally, Maxigen Biotech Inc entered into strategic partnerships with leading pharmaceutical companies to further develop and market their products globally. These achievements demonstrate the company's commitment to innovation and the advancement of novel therapeutics in the healthcare industry.

Maxigen Biotech Inc is primarily present in the United States.

Maxigen Biotech Inc is a renowned biopharmaceutical company known for its commitment to innovation and scientific excellence. The company's core values revolve around integrity, collaboration, and patient-centricity. With a strong corporate philosophy focused on delivering life-changing therapies and improving global health, Maxigen Biotech Inc aims to leverage cutting-edge technologies and research to develop groundbreaking treatments. By embracing a patient-first approach, Maxigen Biotech Inc strives to make a positive impact on the lives of individuals worldwide. Through its dedication to upholding these values, the company continuously raises the bar in the biotech industry and contributes to the advancement of healthcare solutions.

7 analysts currently rate the Maxigen Biotech stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Maxigen Biotech to generate revenue of 459.00 M TWD and earnings per share of 0.84 TWD.

Maxigen Biotech Analyst Price Targets 2026

Converted at the current exchange rate, the Maxigen Biotech share trades at 1.08 EUR (40.40 TWD).

Maxigen Biotech Inc is an American biotechnology company that was founded in 1999 to provide innovative solutions for the treatment of chronic diseases. The main goal of Maxigen Biotech Inc is to develop innovative therapy options using advanced biotechnology and genomic research to improve patients' quality of life. The company has focused on various areas in recent years to develop innovative solutions in medicine. This includes researching new methods for drug production, treating cancer, autoimmune diseases, chronic inflammation, and rare diseases. There is also a focus on vaccine development. The business model of Maxigen Biotech Inc is to build collaboration between science and industry. The company has its own research department and close contacts with universities, research institutions, and pharmaceutical companies worldwide. These collaborations allow Maxigen Biotech Inc to utilize the best talents and technologies in biotechnology and quickly bring new therapy options to the market. Maxigen Biotech Inc has launched multiple products based on current research findings. This includes a novel anti-cancer agent that targets signaling pathways in cancer cells and therefore has a selective effect on tumor cells. Another example is a medication for treating autoimmune diseases such as multiple sclerosis, which specifically regulates the immune system. The company also has a division for the production of biological drugs. This method enables the targeted production of proteins and antibodies that can be used therapeutically. Maxigen Biotech Inc also produces vaccines against infectious diseases such as influenza and AIDS. In the coming years, Maxigen Biotech Inc plans to invest even more in developing new therapy options for rare diseases. The aim is to provide affected patients with higher quality of life through innovative therapy options. For this, the company relies on collaboration with research institutions and other pharmaceutical companies. Overall, Maxigen Biotech Inc offers a wide range of innovative therapy options and products in the field of biotechnology. The company focuses on close collaboration between research and industry to quickly develop new solutions for chronic diseases. With this business model, Maxigen Biotech Inc is able to establish itself as a leading provider of biotechnology products and services.

The expected revenue of Maxigen Biotech is 459.00 M TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Maxigen Biotech is 75.58 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Maxigen Biotech is currently 47.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Maxigen Biotech stock.

The price-to-sales ratio (P/S) of Maxigen Biotech is currently 7.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Maxigen Biotech stock.

The Eulerpool Quality Score for Maxigen Biotech is 6/10.

The ISIN of Maxigen Biotech is TW0001783009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Maxigen Biotech is 1783.TW. The ticker symbol is used to trade Maxigen Biotech shares on the stock exchange.

Over the past 12 months, Maxigen Biotech paid a dividend of 0.83 TWD . This corresponds to a dividend yield of about 2.05 %. For the coming 12 months, Maxigen Biotech is expected to pay a dividend of 0.95 TWD.

The current dividend yield of Maxigen Biotech is 2.05 %.

Maxigen Biotech pays a dividend, distributed in the months of , , , .

Maxigen Biotech paid dividends every year for the past 3 years.

For the upcoming 12 months, dividends amounting to 0.95 TWD are expected. This corresponds to a dividend yield of 2.36 %.

Maxigen Biotech is assigned to the 'Non-cyclical consumption' sector.

To receive the latest dividend of Maxigen Biotech from amounting to 0.83 TWD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Maxigen Biotech distributed 1 TWD as dividends.

The dividends of Maxigen Biotech are distributed in TWD.

All fundamentals and in-depth analysis of Maxigen Biotech

Our stock analysis for Maxigen Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Maxigen Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Maxigen Biotech Stock
Maxigen Biotech Revenue→
Maxigen Biotech Stock
Maxigen Biotech Net Income→
Maxigen Biotech Stock
Maxigen Biotech P/E→
Maxigen Biotech Stock
Maxigen Biotech P/S→
Maxigen Biotech Stock
Maxigen Biotech EBIT→
Maxigen Biotech Stock
Maxigen Biotech Dividend→
Maxigen Biotech Stock
Maxigen Biotech Directors Dealings→
Maxigen Biotech Stock
Maxigen Biotech Stocks→
Maxigen Biotech Stock
Maxigen Biotech Market capitalization→
Maxigen Biotech Stock
Maxigen Biotech Debt→
Maxigen Biotech Stock
Maxigen Biotech Liabilities→
Maxigen Biotech Stock
Maxigen Biotech Equity→
Maxigen Biotech Stock
Maxigen Biotech AAQS→
Maxigen Biotech Stock
Maxigen Biotech Employees→
Maxigen Biotech Stock
Maxigen Biotech ROE→
Maxigen Biotech Stock
Maxigen Biotech ROA→
Maxigen Biotech Stock
Maxigen Biotech ROCE→
Maxigen Biotech Stock
Maxigen Biotech News→
Maxigen Biotech Stock
Maxigen Biotech Analyst Price Targets→

Non-cyclical consumption Stocks

Maxindo Karya Anugerah Tbk PTMawana SugarsMaxvalu Tokai CoMatvareexpressen ASMayora Indah Tbk PTMatsukiyoCocokara &Maywufa CoMatahari Putra Prima Tbk PTMcBrideMasoval ASMcCormick & CompanyMasi Agricola SpAAll Stocks A–Z →